Executive Sponsors

Caprion
Covance
VirtualScopics, Inc.

Associate Sponsors

Cancer Genetics
HTG Molecular
IntelliCyt
Neon Therapeutics
Ventana

Supporting Sponsors

Defined health

Exhibitors

Abcam
BioMedical Systems
Biotech Corporation
Loncar Investments
Personalis
Provecs Medical
World Courier

Supporting Partners

Cancer Research Institute
CIMT
SITC

Media Partners

Advances in Modern Oncology Research, AMOR
BioCompare
BioPharm Clinical
BioPharma Dive
Clinical Leader
GEN
K BioSciences
Medical News Today
Pharma VOICE
Technology Networks

IO 360 Supports

Dance Against Cancer
Emily Whitehead Foundation

Overview

The Conference Forum would like to thank everyone involved with the 2nd annual Immuno-Oncology 360° event.

We want to thank our IO supporting partners and sponsors for their insights and support on content and agenda development. In particular, we would like to thank our lead advisors, Dr Axel Hoos (GSK) and Dr James Gulley (NCI), for their unwavering guidance, expertise and enthusiasm to present a unique 360-degree program for cancer immunotherapy.

Hoos_Gulley

​IO360 Co-chairs Dr. Axel Hoos, GSK and Dr. James Gulley, NCI

Jedd_Kate

​Dr. Jedd Wolchok, MSCKK and Kate Woda, The Conference Forum

June

​Dr. Carl June, University of Pennsylvania delivers Keynote at IO360

 

 

 

 

 

 

 

 

 

 

 

With rapid development of cancer immunotherapy drug development, breakthrough FDA approval status, and fast-tracking clinical trials, competition is fierce. The science behind immune-based therapies is driving rapid change. Both small and large companies are racing to bring game-changing therapies to the market and in many cases, partnering to maximize on combination therapies. As a result, innovative approaches and developments are also creating increased momentum for investment/business development opportunities.

June_tcf_advisors

​Left to Right: Dr. Carl June, UPenn, Kate Woda and Valerie Bowling, The Conference Forum, Dr. James Gulley, NCI and Dr. Axel Hoos, GSK

 

The 2nd annual Immuno-Oncology 360° event delved into key areas of business, clinical and scientific advancements including:

  • Business Aspects for IO
  • Differences of Modalities in Immunotherapy
  • Methodological Advances – Investigating Immunotherapies in the Clinic
  • Immunotherapy Practice Altering Clinical Advances
  • Hematologic Malignancies
  • Emerging Biomarkers
  • Randomized Phase II Combination Therapy Trials

IO360° Videos

Save the date for the 3rd Annual Immuno-Oncology 360° program scheduled to take place February 2-3, 2017 in NYC.

Sincerely,

Kate Woda B&W

 

Kate Woda
Conference Director

 

Valerie Bowling New

 

Valerie Bowling
Executive Director

 

Jessica Rothenberg B&W

 

Jessica Rothenberg
Marketing Director

 

Meredith Sands B&W

 

Meredith Sands
Executive Director, Business Development

 

Elizabeth Bard B&W

 

Elizabeth Bard
Business Development Manager

 

Geeta-BW

 

Geeta Bachani
Business Development Manager

 

Bridget Murphy B&W

 

Bridget Murphy
Conference Logistic Planner